Analyst Luca Issi works at RBC and is focused on the Healthcare sector with 111 price targets and ratings documented since 2020 spanning on 16 stocks. Analyst's average stock valuation to be materialised ratio is 28.13% with an average time for price targets to be met of 32.25 days.
Most recent stock forecast was given on WVE, Wave Life Sciences Ltd at 11-Nov-2022.
Luca Issi best performing recommendations are on ARWR (ARROWHEAD PHARMACEUTICALS, INC).
The best stock recommendation documented was for RGNX (REGENXBIO INC) at 5/13/2020. The price target of $42 was fulfilled within 8 days with a profit of $4.72 (12.66%) receiving and performance score of 15.83.
Average potential price target upside